Moderna Increases Production Estimates for COVID-19 Vaccine

January 6, 2021
Jennifer Barrett

Moderna is upping its COVID-19 vaccine production this year, with a baseline estimation of 600 million doses for 2021.

Moderna is increasing the estimated number of doses of its coronavirus disease 2019 (COVID-19) vaccine that it expects to produce to 600 million for 2021, according to a company statement.

To date, approximately 18 million doses have been supplied to the US government since the vaccine, mRNA-1273, received Emergency Use Authorization on December 18, 2020. Additional vaccine doses have also been supplied to the Canadian government following authorization by Health Canada’s Interim Order on December 23, 2020.

The company initially estimated a baseline production of 500 million doses for 2021, before upping that to 600 million. It expects approximately 100 million doses to be available in the US by the end of the first quarter of 2021, with 200 million doses available by the end of the second quarter.

“Our effectiveness in providing early supply to the US and Canadian governments and our ability to increase baseline production estimates for 2021 are both signals that our scale up of mRNA vaccine production is a success,” said Juan Andres, chief technical operations and quality officer at Moderna.

Listen to our recent podcast episode to learn how pharmacies can tap into technology to boost vaccination programs for COVID-19 vaccines.

Reference

Moderna Provides COVID-19 Supply Update. News release. Moderna; January 4, 2020. Accessed January 6, 2020. https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-covid-19-vaccine-supply-update